TUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkey

Basit Öğe Kaydı
dc.contributor.authorAtakan, Nilgun
dc.contributor.authorYazici, Ayca Cordan
dc.contributor.authorOzarmagan, Guzin
dc.contributor.authorInaloz, Huseyin Serhat
dc.contributor.authorGurer, Mehmet Ali
dc.contributor.authorSabuncu, Ilham
dc.contributor.authorKiremitci, Ummuhan
dc.contributor.authorAlper, Sibel
dc.contributor.authorAytekin, Sema
dc.contributor.authorArican, Ozer
dc.contributor.authorPolat, Mualla
dc.contributor.authorDogan, Sibel
dc.contributor.authorAldinc, Emre
dc.date.accessioned2019-10-27T23:11:06Z
dc.date.available2019-10-27T23:11:06Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.abstractPsoriasis is a common inflammatory disease that has a severe impact on quality of life. There is lack of data regarding epidemiological and clinical features of psoriasis patients in Turkey, a country with a population of 76million. The aim of this study was to define the demographic and clinical characteristics, quality of life and treatment patterns of psoriasis patients in Turkey. A cross-sectional observational study was conducted at 40 centers, chosen from geographically diverse locations in Turkey. Patients diagnosed with psoriasis were assessed by investigators who were specialists of dermatology using standardized study questionnaire forms. Dermatology Life Quality Index (DLQI) and EuroQol-5 dimension (EQ-5D) forms were also filled out by each patient. 3971 psoriasis patients were included in this study. 24.2% of plaque psoriasis patients had moderate to severe psoriasis (Psoriasis Area and Severity Index, 10). Mean DLQI was 7.03 +/- 6.02; quality of life was moderately, severely or very severely affected in 49.2% of patients. The most severely affected component of EQ-5D was anxiety/depression. Among all patients, 22.9% were not receiving any treatment, 39.8% were receiving only topical treatment, 11.5% were on phototherapy, 26.1%, were taking conventional systemic agents and 4.1% were on a biologic treatment. 31.3% of psoriasis patients with moderate to severe disease were treated with only topical agents and only 30.5% of moderate to severe psoriasis patients were receiving systemic therapy. Moderate to severe psoriasis has a considerable impact on quality of life. Treatment in Turkey of patients with moderate to severe psoriasis is insufficient.en_US
dc.description.sponsorshipPfizerPfizeren_US
dc.description.sponsorshipThis study was sponsored by Pfizer, employees of Pfizer contributed to the design of the study, interpretation of the results and development of the manuscript. Editorial assistance with manuscript development was provided by Susanne Gilbert of ACUMED (New York, NY, USA) and was funded by Pfizer. The authors acknowledge the contributions of the investigators: Dr Esra Ozsoy Adisen, Dr Vahide Baysal Akkaya, Dr Aye Esra Koku Aksu, Dr Hamza Aktas, Dr Aynur Akyol, Dr Sema Altun, Dr Ilknur Altunay, Dr Aysegul Altuntas, Dr E. Esra Arpag, Dr Burcak Bozdemir Aral, Dr Safak Arslan, Dr Gokcen Balci, Dr Emel Bulbul Baskan, Dr Cemal Bilac, Dr Ferihan Uslu Bilgin, Dr Ilgul Bilgin, Dr Omer Calka, Dr Burcin Dogan, Dr Tugba Ekmekci, Dr H. Meral Eksioglu, Dr Sevinc Elinc, Dr Mustafa Teoman Erdem, Dr Bema Sanli Erdogan, Dr Ayten Ferahbas, Dr Gonca Gokdemir, Dr Seyma Celik Gulecol, Dr Asli Gulel, Dr Ulas Guvenc, Dr Asli Hapa, Dr Seval Dogruk Kacar, Dr Basak Kandi, Dr Isin Kilic Karaarslan, Dr Yelda Karincaoglu, Dr Aylin Haskok Kazanci, Dr Sevgi Kilic, Dr Yildiz Kilinc, Dr Saliha Can Kirbas, Dr Rafet Koca, Prof. Dr Mukadder Kocak, Dr Selma Korkmaz, Dr Adem Kosklu, Dr Ergun Kusku, Dr Nurdan Seda Kutlu, Dr Hamdi R. Memisoglu, Dr Ahmet Metin, Dr Inci Mevlitoglu, Dr Ozgul Mustu, Dr Tuba Ozceyhan, Dr Mustafa Ozdemir, Dr Ayes Sebnem Ozkan, Dr Serap Ozturkcan, Dr Hatice Ozyigit, Dr Mustafa Turhan Sahin, Dr Muzaffer Sahin, Dr Mehmet Sakman, Dr Sezai Sasmaz, Dr Neslihan Sendur, Doc. Dr Nilgun Senturk, Dr Gamze Serarslan, Dr Engin Sezer, Dr Funda Tas, Dr Nazan Sengun Taslidere, Dr Nergiz Turan, Dr Muge Turkmen, Dr Isin Zehra Uluc, Dr Cahit Yavuz, Dr I. Halil Yavuz, Dr Savas Yayli, Dr Eylem Yilmaz, Dr Yasar Yilmaz, Dr Tulin Yuksel and Dr Ilknur Yorgun.en_US
dc.identifier.doi10.1111/1346-8138.13081en_US
dc.identifier.endpage304en_US
dc.identifier.issn0385-2407
dc.identifier.issn1346-8138
dc.identifier.issue3en_US
dc.identifier.pmid26365805en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage298en_US
dc.identifier.urihttps://doi.org/10.1111/1346-8138.13081
dc.identifier.urihttps://hdl.handle.net/11454/53018
dc.identifier.volume43en_US
dc.identifier.wosWOS:000371889000011en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWiley-Blackwellen_US
dc.relation.ispartofJournal of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectcross-sectionalen_US
dc.subjectpsoriasisen_US
dc.subjectquality of lifeen_US
dc.subjectseverityen_US
dc.subjecttreatmenten_US
dc.titleTUR-PSO: A cross-sectional, study investigating quality of life and treatment status of psoriasis patients in Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu